Hyun J Kim1, Donald P Tashkin2, David W Gjertson1, Matthew S Brown3, Eric Kleerup2, Semin Chong4, John A Belperio2, Michael D Roth2, Fereidoun Abtin3, Robert Elashoff5, Chi-Hong Tseng6, Dinesh Khanna7, Jonathan G Goldin3. 1. Department of Radiological Science, Center for Computer Vision Imaging Biomarker, David Geffen School of Medicine at UCLA, Los Angeles, California, USA Department of Biostatistics, Fielding School of Public Health at UCLA, Los Angeles, California, USA. 2. Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. 3. Department of Radiological Science, Center for Computer Vision Imaging Biomarker, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. 4. Department of Radiology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. 5. Department of Biostatistics, Fielding School of Public Health at UCLA, Los Angeles, California, USA Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. 6. Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. 7. Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
OBJECTIVES: The aim is to investigate whether the 12-month quantitative changes in high-resolution CT (HRCT) measures of interstitial lung disease (ILD) are different, and to understand how they change, in patients with scleroderma-related ILD who receive drug therapy versus placebo. METHODS: HRCT images were acquired at baseline and at 12 months in 83 participants in Scleroderma Lung Study I, a clinical trial comparing treatment with oral cyclophosphamide versus placebo. A computer-aided model was used to quantify the extent of fibrotic reticulation, ground glass and honeycomb patterns and quantitative ILD (QILD: sum of these patterns) in the whole lung and the lung zone (upper, middle or lower) of maximal disease involvement. RESULTS: Mean QILD score decreased by 3.9% in the cyclophosphamide group while increasing by 4.2% in the placebo group in the most severe zone (p=0.01) and decreased by 3.2% in the cyclophosphamide group while increasing by 2.2% in the placebo group in the whole lung (p=0.03). Transitional probabilities demonstrated greater changes from a fibrotic to either a ground glass or normal pattern in the cyclophosphamide group and the reverse in the placebo group. CONCLUSIONS: Changes in quantitative HRCT measures of ILD provide a sensitive indication of disease progression and response to treatment. TRIAL REGISTRATION NUMBER: NCT00004563; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: The aim is to investigate whether the 12-month quantitative changes in high-resolution CT (HRCT) measures of interstitial lung disease (ILD) are different, and to understand how they change, in patients with scleroderma-related ILD who receive drug therapy versus placebo. METHODS: HRCT images were acquired at baseline and at 12 months in 83 participants in Scleroderma Lung Study I, a clinical trial comparing treatment with oral cyclophosphamide versus placebo. A computer-aided model was used to quantify the extent of fibrotic reticulation, ground glass and honeycomb patterns and quantitative ILD (QILD: sum of these patterns) in the whole lung and the lung zone (upper, middle or lower) of maximal disease involvement. RESULTS: Mean QILD score decreased by 3.9% in the cyclophosphamide group while increasing by 4.2% in the placebo group in the most severe zone (p=0.01) and decreased by 3.2% in the cyclophosphamide group while increasing by 2.2% in the placebo group in the whole lung (p=0.03). Transitional probabilities demonstrated greater changes from a fibrotic to either a ground glass or normal pattern in the cyclophosphamide group and the reverse in the placebo group. CONCLUSIONS: Changes in quantitative HRCT measures of ILD provide a sensitive indication of disease progression and response to treatment. TRIAL REGISTRATION NUMBER: NCT00004563; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Jonathan G Goldin; Grace Hyun J Kim; Chi-Hong Tseng; Elizabeth Volkmann; Daniel Furst; Philip Clements; Matt Brown; Michael Roth; Dinesh Khanna; Donald P Tashkin Journal: Ann Am Thorac Soc Date: 2018-11
Authors: Grace Hyun J Kim; Donald P Tashkin; Pechin Lo; Matthew S Brown; Elizabeth R Volkmann; David W Gjertson; Dinesh Khanna; Robert M Elashoff; Chi-Hong Tseng; Michael D Roth; Jonathan G Goldin Journal: Arthritis Rheumatol Date: 2019-12-26 Impact factor: 10.995
Authors: Elizabeth R Volkmann; Donald P Tashkin; Myung Sim; Grace Hyun Kim; Jonathan Goldin; Philip J Clements Journal: J Scleroderma Relat Disord Date: 2018-12-17
Authors: Suzanne Kafaja; Philip J Clements; Holly Wilhalme; Chi-Hong Tseng; Daniel E Furst; Grace Hyun Kim; Jonathan Goldin; Elizabeth R Volkmann; Michael D Roth; Donald P Tashkin; Dinesh Khanna Journal: Am J Respir Crit Care Med Date: 2017-11-03 Impact factor: 30.528